WELCOME TO The Biotechnology REPORT
Newsletter | Member Login | Signup
Home > Companies > BIOTECH RESOURCES GROUP, LLC
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
Conference
Webinar
CELL AND GENE THERAPY
Biotimize | September 06, 2022
Biotimize, a functional growth-stage biotechnology as a service company with a mission to transform lives through biotechnology, today announced the opening of a $30 million Series A fundraising round. The investment will enable Biotimize to build the first biological CDMO in Brazil and to become the first end-to-end biological CDMO in South America. Brazilian universities, startups, and medium-large companies face enormous challenges in developing biological Active Pharmaceutical...
iXCells Biotechnologies | September 30, 2022
iXCells Biotechnologies a high growth provider of cell-based products and discovery services to the academic, biotech and pharmaceutical communities worldwide, with special focus on primary and induced pluripotent stem cell derived cellular models, today announced receiving a growth investment from Connecticut-based Great Point Partners a private investment firm focusing on the healthcare industry. “iXCells is delighted to join GPP’s portfolio of ...
Sysmex Corporation | May 17, 2021
Sysmex Corporation and ThinkCyte, Inc. announced today the signing of joint development and investment agreements for the commercialization of an AI-based cell analysis technology in May 2021. The development of novel testing and diagnostic technologies of high clinical utility is being pursued to improve the precision of diagnoses and maximize treatment as healthcare becomes more accurate and personalized at an increased pace - in combination with the advancement of technology. M...
Arbor Vita | June 08, 2020
Arbor Vita announced today the availability of its CoVisa™ IgG ELISA-based test for antibodies associated with the novel coronavirus (COVID-19). The test has been found to have a 100 percent sensitivity (positive percentage agreement), and 99.24 percent specificity (negative percentage). Additional validation testing is ongoing in independent laboratories. The company has notified the U.S. Food and Drug Administration under the Emergency Use Authorization (EUA) process.Arbor Vita'...
Article
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Welcome back!
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE